June 19, 2020 / 5:29 AM / 2 months ago

Roche says prostate cancer drug hit one trial goal, missed another

ZURICH, June 19 (Reuters) - Swiss drugmaker Roche said on Friday its experimental medicine ipatasertib hit one goal of a late-stage clinical trial against a small slice of patients with a kind of prostate cancer but fell short in the overall study population.

The drug, mixed with other medicines, hit its target of radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC) whose tumours had PTEN loss.

In the broader study group, however, the target of rPFS was not met, Roche said in a statement, adding the trial will continue to the next analysis. (Reporting by John Miller; editing by Thomas Seythal)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below